Member Info for jdt1990

I feel the placing was great business in all honesty and perfectly opportunistic. SP spiked on the Covid herd throwing money at anything that had any slight hint of the word. Raised £40m odd at a minimal discount (to average SP) which included some big name II's, on AIM I would say that is a strong move.
That placing was was explicitly noted as being for expanding and developing the therapeutics business. Moving along projects that without that money would have been shelved for years.
So again this boils down to there being 2 camps. The Covid herd who want an LFT RNS and only that will do and LTH's who see this as a "side project"(albeit large one) which shouldn't detract from what the buisness fundamentally was set up to do. That is:
1. Put a use case out there for Affimers as revolutionary in the biomed space. That is being shows with RNS's like today and in fact, with the Covid work too in the LFT's themselves and Deepverge for example)
2. Progress the oncology work in the therapeutics space. Cash now in bank to do this and AVA600 hopefully lands by end of year.
So yes, if you got in here at £2+ and were spiked looking for a 500% return in a week, I get your frustration. But for me personally having been here long beofre any Covid related work. This is playing out very very nicely.

https://economicalpha.blog/2020/12/11/gdxj-mvis-rebalance-q4-2020/
Yep upped to 1.65% JoeBass. So their 0.98% holding as of COB 17/12 doesn't factor in any Friday buying. Ill keep checking VanEck's website today to see what the holding is as of COB 18/12 is....

The problem with anything Covid relates is the goalposts are always moving. Hence why I am not so concerned about delays in this area, especially when we are reliant on third parties for a good portion of the work. If this was a Covid/LFT company, I would probably be worried.
However, it isn't and progress continues in many other areas (such as todays RNS). So if AS delivers AVA600 as stated multiple times in RNS's by the end of the year, I will be more than comfortable that the Co doesn't have any issue with delivering.

craiga24 - don't disagree on your comment "Don't get me wrong not a bad RNS as in its not reporting everything has failed but people need to put the party poppers away there is nothing significant in there" in relation to the LFT/Covid avenues.
However, what's positive is what is NOT mentioned in the RNS. AVA600 is not cited anywhere and we were due filing on that before the year end so that could still land in the next couple of days. Something finally fully in our control and in my opinion way bigger than any of the LFT work.
(This next comment isn't aimed at you) but many came here in the Covid rush and are sadly waiting for one RNS only, nothing else will do for them. So much more going on with this business that delays in that area from third parties I have little concern over.
If AVA600 does land on time - that is a material milestone for the therapeutics business!

Agreed oxygen and good riddance to all the CoVid quick buck chasers. For me, as much as if it does come off it will be a company changing product, the Covid related work has really detracted from all the fantastic other things AVCT are working on. We are currently viewed as a one trick pony and it should be the complete opposite.
AVA news can still land before year end (in our control)
More licensing agreements (who knows?)
What is clear to me here though is Affimers are steadily growing in stature among the biomed industry. As a business model, monetising your IP is the perfect way to go. You have the product and the IP, so let people pay you to use it....simple but effective.
For anyone moaning about there not being "clear revenue numbers" in this RNS. Of course commercial term are sensitive! Why would AVCT release the terms as if you plan to have tens, hundreds or thousands of these agreements. Once customers know what others are being charged, you have set your price...

Saintsmith - nice try - NCYT's RNS just says that their existing products work for the new strain. What is not to say AVCTs delays in getting a product to market is partially due to this?

MB - so based on your comments you have visibility on what royalties we will receive for Astrea's purification products that contain Affimer reagents and what volumes and prices Astreas product sell at??? This is the ideal business model for Affimers. You let people pay you to generate your product in house for which you own the IP (i.e. no work required on your end) and take a cut of whatever they sell that uses your product going forward.
Money for doing nothing sounds good to me.
I'm not going to say I am not disappointed at the lack of news on the fronts we were told would be Q4 but to try and undermine the content of this RNS is pretty pathetic from you really.

Does it not occur to the naysayers here (obviously not to some of the trolls) that work is being done on other avenues such as these licensing deals as we are quite simply waiting for third parties (production and validation) to pull their fingers out of their a*ses and get done what we need them to get done!

You have no idea what the royalty agreements are on this deal for Astrea's purification products that contain Affimers. That is likely where the financial benefits will come....

Same here - so they progressed on some progress - which when you break it down they have competed some internal due diligence, I'm sure due to Covid LC sees this as "a material undertaking". Well sorry LC, plenty of other companies are managing to operate very successfully in these conditions.
This can't go any further until:
· Sloane is successfully admitted to trading on the London Stock Exchange (any update on this - no timescale indicated?)
· All applicable necessary, regulatory, statutory, board and other approvals or consents having been obtained by the parties (well this is clearly where the leg work is!! How long will this take and how much will it cost?!)
What is really the kicker for me here is that these projects wont even be directly owned by KIBO so us holders here wont reap the full benefits. We will have an indirect shareholding that I am sure will be diluted/consolidated to keep the lights on.
Why have all producing projects been spun out and KIBO holders been left holding the baby?

Shame Matt Hanco** continues to push the "silver bullet" vaccine rhetoric, watched him on Andrew Marr this morning, completely irresponsible. It's great to have one don't get me wrong, but this is going to take a long time to roll out at levels that will get us "back to normal", not to mention the fact I can potentially see issues coming to light with what nobody can argue has been a hurried vaccine approval process.
The need for testing and therapies will continue for years to come, if this gets the nod, VELA could see some material upside form that investment. SNG is a very good example of this!

Interesting snippet from a teacher friend of ours in the Liverpool area.
“ We got an announcement on Thursday night / Friday morning that in Jan we are expected to train up on testing so we can test pupils twice a week and we have to be tested once a week”
Can’t see that being a success with brain tickler swabs on kids taken by their teachers! Needs a less invasive method....who has one of those?

Well that’s Innova’s reputation shot if it wasn’t already! This is exactly what we have been saying to the moaners saying where is our test...if you’re going to do it, do it properly first time! Not a shoddy cheap job to try being in a quick opportunistic windfall. This really does start to point to Affimers potentially having their chance to shine now.

Not sure how many more times we need to say this, for the newer swab based LFT tech transfer is not required as BBI had all existing components ready to manufacture. That was very clearly stated in the RNS!!!

urbanracer whilst you have a pop at me, my actual point was In relation to the comment from someone earlier about not releasing news on New Year’s Eve because the market is quiet and it wouldn’t have the anticipated SP impact. That is 100% not allowed.
Think it would be good for you to enlighten us all under what circumstances they can hold back Scally news?

RightOn - couldn’t agree more. Think it’s smart business to preserve capital especially in these uncertain times. So many AIM companies stretch themselves and when inevitable delays happen they are caught short. Shrewd move I think here to hedge against any further delays, although they still seem confident of a Q1 pour.
The gold loan is $3m - even at 17% interest ($500k per year) this can be paid off in a heartbeat once gold produced. It’s about 4000oz worth - there is over 120,000 oz in the south pit alone!

Let’s also just be clear they can’t hold back Scally results to allow “the best day for interest”. If they are ready they have to be released it’s price sensitive info!

Louis Coetzee, CEO of Kibo Energy, commented, "We are satisfied with developments of the Baobab project”
Haha well Louis I’ll tell you what - I and many many other shareholders aren’t!
Laguna not sure how long you’ve been in here but this company has delivered nothing but empty promises, dilution for shareholders and a salary at their expense for LC.
To say just sell is ridiculous. Some are so far underwater it isn’t worth selling - I’m personally 98% down here and why the hell should I have any faith in this Co to average down! Sadly life isn’t a bottomless pit of money. I’d think about what has happened here over the years before posting comments like yours below.
Very naive to think because someone has said they’re pleased with progress anything is going to happen soon.
Anything of value this business ever owned has been spun off, Kibo shareholders received no direct holding in those new Co’s (KAT and MED for example) and the indirect holding they were left with gets diluted to oblivion through placings...it’s nothing but a joke...simple as.
So yes if you’re in at 0.19p it’s a gamble worth taking something may happen. But not everyone has that luxury and are allowed a moan.
For me, the only hope here is KAT comes off big time with Blyvoor and Haneti which filters through here before it’s diluted and consolidated into administration!

He sold too early here and is frustrated at having to wait for AVCT.
He’s a complete plank Arnold and starting to look very very silly. Do yourself a favour, pack up the bitterness and move on!
If Scally was a dud GH would have left with immediate effect and been free to sell his shares before and bad news hit the market.
He explained his reason for leaving in the proactive interview - watch it - I’m sure you know all this already though.
Why would you stay on over Xmas when Scally news is due and have your huge shareholding locked in over that period if it was a dud?
Common sense buddy

Well it’s always morning somewhere in the world so you’ve covered your bases there pal, congratulations on joining the elite “well get an update one day” crew